ADC Therapeutics SA financial data

Symbol
ADCT on NYSE
Location
Epalinges, Switzerland
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 10 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 460% % -2.7%
Quick Ratio 23% % 22%
Debt-to-equity -240% % 18%
Return On Equity 66% % -27%
Return On Assets -47% % -1.1%
Operating Margin -149% % 19%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 127,044,356 shares 28%
Common Stock, Shares, Outstanding 125,748,762 shares 27%
Entity Public Float $136,400,000 USD -21%
Common Stock, Value, Issued $11,080,000 USD 32%
Weighted Average Number of Shares Outstanding, Basic 127,067,540 shares 31%
Weighted Average Number of Shares Outstanding, Diluted 127,067,540 shares 31%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $81,357,000 USD 15%
Revenue from Contract with Customer, Excluding Assessed Tax $15,750,000 USD -13%
Research and Development Expense $104,005,000 USD -5.1%
Selling and Marketing Expense $43,374,000 USD -1.5%
General and Administrative Expense $36,559,000 USD -13%
Costs and Expenses $202,856,000 USD 0.68%
Operating Income (Loss) $121,499,000 USD 7%
Nonoperating Income (Expense) $20,109,000 USD 21%
Income Tax Expense (Benefit) $1,015,000 USD 511%
Net Income (Loss) Attributable to Parent $142,623,000 USD 9.6%
Earnings Per Share, Basic -1.12 USD/shares 31%
Earnings Per Share, Diluted -1.12 USD/shares 31%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $261,338,000 USD 4.2%
Inventory, Net $4,184,000 USD 86%
Other Assets, Current $6,084,000 USD -36%
Assets, Current $306,335,000 USD 5.2%
Property, Plant and Equipment, Net $0 USD -100%
Operating Lease, Right-of-Use Asset $1,297,000 USD -84%
Other Assets, Noncurrent $1,217,000 USD 4.8%
Assets $323,150,000 USD 0.36%
Accounts Payable, Current $9,175,000 USD -49%
Accrued Liabilities, Current $57,988,000 USD -7.1%
Liabilities, Current $70,163,000 USD -13%
Deferred Income Tax Liabilities, Net $789,000 USD -59%
Operating Lease, Liability, Noncurrent $1,034,000 USD -87%
Other Liabilities, Noncurrent $2,810,000 USD 15%
Liabilities $508,984,000 USD -3%
Accumulated Other Comprehensive Income (Loss), Net of Tax $517,000 USD 64%
Retained Earnings (Accumulated Deficit) $1,635,941,000 USD -9.6%
Stockholders' Equity Attributable to Parent $185,834,000 USD 8.3%
Liabilities and Equity $323,150,000 USD 0.36%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $56,334,000 USD -28%
Net Cash Provided by (Used in) Financing Activities $271,000 USD -24%
Net Cash Provided by (Used in) Investing Activities $264,000 USD 50%
Common Stock, Shares, Issued 128,310,010 shares 26%
Common Stock, Par or Stated Value Per Share 0.08 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $261,338,000 USD 4.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities $3,594,000 USD -7.8%
Deferred Tax Assets, Valuation Allowance $250,969,000 USD 14%
Deferred Tax Assets, Gross $251,758,000 USD 14%
Operating Lease, Liability $1,573,000 USD -83%
Depreciation $705,000 USD -47%
Payments to Acquire Property, Plant, and Equipment $264,000 USD -50%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $141,719,000 USD 11%
Lessee, Operating Lease, Liability, to be Paid $1,725,000 USD -84%
Property, Plant and Equipment, Gross $1,381,000 USD -87%
Operating Lease, Liability, Current $538,000 USD -61%
Lessee, Operating Lease, Liability, to be Paid, Year Two $166,000 USD -90%
Lessee, Operating Lease, Liability, to be Paid, Year One $583,000 USD -67%
Operating Lease, Weighted Average Discount Rate, Percent 0.033 pure -28%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $152,000 USD -90%
Lessee, Operating Lease, Liability, to be Paid, Year Three $166,000 USD -90%
Deferred Tax Assets, Operating Loss Carryforwards $165,508,000 USD 10%
Unrecognized Tax Benefits $6,798,000 USD -9.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $166,000 USD -91%
Additional Paid in Capital $1,439,749,000 USD 12%
Deferred Tax Assets, Net of Valuation Allowance $789,000 USD -59%
Interest Expense $49,945,000 USD 2.9%